Table III.
Grade ≥3 Adverse Events at Least Possibly Related to Pembrolizumab in the Safety Population (N=18)
| Toxicity | Total N (%) | Grade N (%) | ||
|---|---|---|---|---|
| 3 | 4 | 5 | ||
| Febrile Neutropenia | 1 (6) | 1 (6) | ||
| Hemophagocytic Lymphohistiocytosis (HLH) | 1 (6) | 1 (6) | ||
| Lung Infection | 1 (6) | 1 (6) | ||
| Hyperglycemia | 1 (6) | 1 (6) | ||
| Hyponatremia | 1 (6) | 1 (6) | ||
| Muscle Weakness | 1 (6) | 1 (6) | ||
| Peripheral Sensory Neuropathy | 1 (6) | 1 (6) | ||
| Pleural Effusion | 1 (6) | 1 (6) | ||
| Pneumonitis | 2 (11) | 1 (6) | 1 (6) | |
| Rash | 2 (11) | 1 (6) | 1 (6) | |
| Hypotension | 1 (6) | 1 (6) | ||
| Vasculitis | 1 (6) | 1 (6) | ||